Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Study sponsor: Annexon, Inc. · ANNX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-04-20Actual
Enrollment · participants242Actual
Source updated2025-05-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.